GLP-1/glucagon dual-acting agonist (obesity / diabetes)

The dual-acting GLP-1/glucagon agonist activates both the GLP-1 and glucagon receptors, two key gut hormone receptors, and may offer better blood glucose and weight loss control than currently available single-agonist treatments. The compound builds partly on the effects of the natural gut hormone oxyntomodulin, which has been shown to decrease food intake and increase energy expenditure in humans.

More information: scientific publications

Next steps

The dual acting GLP-1/glucagon agonist will advance to Phase 2 clinical testing based on the safety and tolerability and the favorable weight loss potential in individuals with a BMI up to 40 kg/m2. The Phase 2 trial will be a dose-finding, placebo and active comparator clinical proof of concept trial in patients with obesity and type 2 diabetes, and is expected to be initiated in late 2019.


The global prevalence of obesity has more than doubled since 1980. In 2014, more than 1.9 billion adults were classified as overweight and over 600 million of these were obese.*

http://www.who.int/mediacentre/factsheets/fs311/en/


Collaboration with Boehringer Ingelheim

Zealand has two collaborations with Boehringer Ingelheim, where they fund all research, development and commercialization activities. Zealand is eligible to receive royalties and milestone payments as follows:

GLP-1/glucagon dual-acting agonist

  • EUR 365 million outstanding in milestone payments

  • Initiation of Phase 2 trial will trigger a milestone payment of EUR 20 million to Zealand Pharma

  • High single-digit to low double-digit percentage royalties on global sales